Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma

Press Release: Lisp-cell meets primary endpoint of EFS over Auto after first relapse in DLBCL. OS data not yet mature. very limited data currently available for review, but hopefully we will see it presented at ASH.

Read the full article here

Related Articles